The short answer
A small study found lower diltiazem exposure with gugulipid. Discuss the exact guggul product before use, but do not rely on an eight-hour gap: the study measured blood samples for eight hours and did not test that spacing.
What this answer covers
Oral diltiazem with gugulipid, an extract linked in NLM terminology to Commiphora wightii/C.mukul. Evidence does not authenticate every whole-plant or resin product.
- Supplement or preparation
- Commiphora wightii
- Medication ingredient
- diltiazem
What the original study found
Seven healthy men received a single 60 mg oral diltiazem dose with or without 1 g gugulipid in a crossover study. Peak concentrations and exposure measured through eight hours fell significantly. The study did not measure loss of angina or BP control in patients.
Eight hours was the measurement window
Blood was sampled hourly for up to eight hours. That is not evidence that taking the supplement eight hours before or after diltiazem prevents the effect. The study also does not define a dose adjustment for extended-release diltiazem.
Match the studied extract
NLM’s substance record links gugulipid with Commiphora wightii extract and C.mukul extract. The historical study abstract gives limited product characterization. Whole-plant powders, different resin extracts and combination products cannot be assumed to deliver the same exposure.
Discuss use before changing therapy
Show the prescriber or pharmacist the extract strength and daily dose. They can decide whether to avoid the product or monitor treatment response. Do not increase diltiazem or stop it yourself. Report worsening BP control or angina promptly and follow your existing plan for chest pain.
Evidence and practical considerations
Absorption & effectiveness
Single-dose gugulipid reduced early diltiazem exposure in seven healthy men; this supports a preparation-limited concern, not a validated eight-hour dosing rule.
- Exact scope
- Oral diltiazem with gugulipid, an extract linked in NLM terminology to Commiphora wightii/C.mukul. Evidence does not authenticate every whole-plant or resin product. with Current RxNorm confirms diltiazem RxCUI 3443 IN. Oral hydrochloride once-daily capsules; immediate-release single-dose originals explicitly distinguished. No transfer to topical fissure treatment or IV administration.
- Medication form and route
- Oral
What remains uncertain
- Abstract-only seven-person single-dose trial, early AUC and incompletely described extract. No validated eight-hour gap, ER equivalence or clinical failure outcome.
Factors that may matter: Exact preparation and dose; Oral formulation; Blood pressure and pulse; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed diltiazem hydrochloride extended-release capsules.
Avoid known CYP3A4 inducers: rifampin lowered concentrations to undetectable. Bradycardia, conduction and hypotension warnings apply.
How this applies: Exact ingredient through the stated labeled salt and oral formulation. Current RxNorm confirms diltiazem RxCUI 3443 IN. Oral hydrochloride once-daily capsules; immediate-release single-dose originals explicitly distinguished. No transfer to topical fissure treatment or IV administration.
Other-drug inducer magnitudes not transferred. Guggul eight-hour sampling is not spacing; small conflicting grapefruit juice studies retained.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Seven healthy men in the diltiazem arm of a randomized crossover.
Peak concentration and AUC measured through eight hours were significantly reduced.
How this applies: Exact preparation and endpoint boundaries retained; this is not a measured diltiazem combination unless explicitly stated.
Abstract-only; no clinical disease-control outcomes, no tested eight-hour separation, limited extract characterization and no ER combination trial.
Source 3: Substance identity record
pubchem.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Substance terminology.
Identifies the extract terminology bridge used for the original study.
How this applies: Explicit extract-only bridge.
Does not authenticate the historical study batch or prove every whole-plant product equivalent. Browser HTML was an access-denied page; successful API JSON is the actual identity source.
Source 4: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
diltiazem is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: 9e59a2f8e13963f9
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.